Very recently, we showed that indeed administration of CXCL10-Ig in a clinical set-up of myeloma that CXCL10-Ig could be used for immunotherapy of this disease, and that aside from enhancing antitumor immunity, it directly suppresses tumor growth (79). Here, CXCL10 is linked to neoplasm.